
CorFlow’s MOCA-II Trial Approved by FDA to Advance Heart Attack Treatment
FDA Approves CorFlow’s MOCA-II IDE Pivotal Trial to Advance Breakthrough Heart Attack Technology CorFlow Therapeutics AG, a Swiss-based medtech innovator specializing in cardiovascular care and microvascular disease, has reached a major milestone in the development of its cutting-edge heart attack…












